- Report
- December 2021
- 141 Pages
Global
From €10629EUR$10,995USD£9,136GBP
- Report
- July 2020
- 1740 Pages
Global
From €4640EUR$4,800USD£3,988GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£831GBP
- Report
- April 2023
- 77 Pages
Global
From €3500EUR$3,878USD£3,114GBP
Tasigna is a brand of medication used to treat certain types of leukemia, a type of cancer of the blood and bone marrow. It is a tyrosine kinase inhibitor, which works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Tasigna is used to treat chronic myeloid leukemia (CML) in adults and children, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults. It is usually taken in combination with other medications.
Tasigna is manufactured by Novartis, a Swiss multinational pharmaceutical company. Other companies in the leukemia drug market include Bristol-Myers Squibb, Pfizer, and Celgene. Show Less Read more
